Abstract: The invention relates to a recombinant protein fabricated in a baculovirus system, of which the essential constitutive polypeptide sequence is that of a C-terminal fragment of 19 kilodalton (p19) of the surface protein 1 (protein MSP-1) of the merozoite parasite of the Plasmodium type, particularly Plasmodium falciparum, which is infectious for humans, said C-terminal fragment remaining normally anchored at the surface of the parasite at the end of its penetration phase into human erythrocytes, in the occurrence of an infectious cycle. Said recombinant protein is applicable to the production of vaccines against malaria.
Type:
Grant
Filed:
February 14, 1997
Date of Patent:
October 25, 2005
Assignees:
Institute Pasteur, New York University
Inventors:
Shirley Longacre-Andre, Charles Roth, Faridabano Nato, John W. Barnwell, Kamini Mendis
Abstract: The present invention relates to peptides and polypeptide derived from the submaxillary gland of the rat. In particular, the present invention discloses a purified peptide of formuls: X-His-Asn-Pro-Y in which X represents a Gln or Pro-Glu residue and Y represents an OH group or residue of a basic amino acid. The present invention also relates to corresponding polyclonal and monoclonal antibodies as well as corresponding hybridomas. The products of the present invention are useful for therapeutic, diagnosis and detection purposes.
Abstract: A modified bioluminescent system comprising a fluorescent molecule covalently linked with a photoprotein, wherein said link between the two proteins has the function to stabilize the modified bioluminescent system and allowing the transfer of the energy by Chemiluminescence Resonance Energy Transfer (CRET).
Abstract: The present invention relates to recombinant negative strand RNA molecules which may be used to express heterologous proteins in animal cells and/or to construct recombinant viruses able to express heterologous proteins during their multiplication in host animal cells.
Type:
Grant
Filed:
April 17, 2002
Date of Patent:
April 20, 2004
Assignee:
Institute Pasteur
Inventors:
Nicolas Robert Xavier Escriou, Sylvie Van Der Werf, Alexandre Vieira-Machado, Nadia Naffakh
Abstract: Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. Further disclosed are chimeric restriction endonucleases.
Type:
Application
Filed:
January 6, 2003
Publication date:
January 29, 2004
Applicants:
The Children's Medical Center Corporation, The Institute Pasteur
Abstract: Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof.
Type:
Application
Filed:
January 2, 2003
Publication date:
December 11, 2003
Applicants:
The Children's Medical Center Corporation, Institute Pasteur
Abstract: A purified polynucleotide having a chain of nucleotides corresponding to a mutated sequence, which in a wild form encodes a polypeptide implicated in hereditary sensory defect, wherein said mutated purified polynucleotide presents a mutation responsible for prelingual non-syndromic deafness selected from the group consisting of a specific deletion of at least one nucleotide.
Abstract: The present invention relates to recombinant negative strand RNA molecules which may be used to express heterologous proteins in animal cells and/or to construct recombinant viruses able to express heterologous proteins during their multiplication in host animal cells.
Type:
Application
Filed:
April 17, 2002
Publication date:
January 9, 2003
Applicant:
INSTITUTE PASTEUR
Inventors:
Nicolas Robert Xavier Escriou, Sylvie Van Der Werf, Alexandre Vieira-Machado, Nadia Naffakh
Abstract: The present invention relates to pro-apoptotic fragments of the Dengue virus pRM and E glycoproteins, methods of screening for molecules capable of inducing apoptosis and methods of inducing apoptosis in a cell.
Type:
Application
Filed:
June 18, 2001
Publication date:
July 4, 2002
Applicant:
INSTITUTE PASTEUR
Inventors:
Philippe Despres, Marie-Pierre Courageot, Vincent Deubel, Adeline Catteau
Abstract: The invention relates to an isolated immune complex comprising a protein and an antibody that binds with said protein, wherein the protein is selected from the group consisting of gp80 of HIV-2 and gp65 of SIV, wherein said gp80 is a glycoprotein having an apparent molecular weight of 80 kDa, as determined by SDS-PAGE, and further wherein said gp65 is a glycoprotein having an apparent molecular weight of 65 kDa as determined by SDS-PAGE. Also provided are an immunogenic composition comprising an amount of gp80 protein of human immunodeficiency virus type 2 (HIV-2) sufficient to induce an immune response and a pharmaceutically acceptible carrier, and a composition comprising at least one antigen selected from the group consisting of gp80 protein of HIV-2 and gp65SIV.
Type:
Grant
Filed:
December 27, 1994
Date of Patent:
July 17, 2001
Assignee:
Institute Pasteur
Inventors:
Ara G. Hovanessian, Marie-Anne Rey, Anne G. Laurent, Bernard Krust, Luc Montagnier
Abstract: The invention concerns human papillomavirus (HPV) DNA and more particularly the probes derived from these papillomaviruses, as well as the methods of detecting HPV using these probes. These human papillomaviruses are designated as HPV-2d, HPV-10b, HPV-14a, HPV-14b, HPV-15, HPV-17a, HPV-17b, HPV-19, HPV-20, HPV-21, HPV-22, HPV-23, HPV-24, HPV-28, HPV-29, HPV-31, HPV-32, HPV-IP2 and HPV-IP4.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
March 2, 1999
Assignees:
Institute Pasteur, Institute Nationale de la Sante et de la Recherche Medicale
Inventors:
Gerard Orth, Sylvie Beaudenon, Michel Favre, Dina Kremsdorf, Odile Croissant, Gerard Pehau-Arnaudet
Abstract: The present invention relates to nucleotide sequences of Actinomycetales, in particular of mycobacteria, to oligonucleotides contained within said nucleotide sequences, to their uses as primers for the synthesis of Actinomycetales DNA and as probes for the detection of DNA and/or the transcription products of Actinomycetales, in particular of mycobacteria, to the products of expression of said sequences, to their uses and to antibodies directed towards the said products, to a method for detecting and identifying Actinomycetales and its uses, as well as to immunogenic compositions comprising the said expression products.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
March 2, 1999
Assignee:
Institut National de la Sante et de la Recherche Mediale-Inserm & Institute Pasteur
Inventors:
Allan Johnson Hance, Bernard Grandchamp-Desraux, Veronique Levy-Frebault, Brigitte Gicquel
Abstract: The present invention relates to nucleotide sequences of Actinomycetales, in particular of mycobacteria, to oligonucleotides contained within said nucleotide sequences, to their uses as primers for the synthesis of Actinomycetales DNA and as probes for the detection of DNA and/or the transcription products of Actinomycetales, in particular of mycobacteria, to the products of expression of said sequences, to their uses and to antibodies directed towards the said products, to a method for detecting and identifying Actinomycetales and its uses, as well as to immunogenic compositions comprising the said expression products.
Type:
Grant
Filed:
February 11, 1991
Date of Patent:
October 6, 1998
Assignees:
Institut National de la Sante et de la Recherche Mediale-Inserm, Institute Pasteur
Inventors:
Allan Johnson Hance, Bernard Grandchamp-Desraux, Veronique Levy-Frebault, Brigitte Gicquel
Abstract: Nucleic acid fragments derived from the HHV6 virus genome, vectors containing said fragments, and their use in the diagnosis of infections involving this virus.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
December 16, 1997
Assignees:
Institute Pasteur, University Paris-VI
Inventors:
Helene Collandre, Luc Montagnier, Henri Agut, Jean-Marie Bechet
Abstract: A viral vector comprising at least a portion of the genome of the HIV virus, a gene encoding gp160 glycoprotein of the envelope of the HIV virus, as well as the elements providing for the expression of the glycoprotein in cells, wherein the gp160 is expressed as a non-cleavable protein.
Type:
Grant
Filed:
May 17, 1995
Date of Patent:
September 30, 1997
Assignee:
Transgene S.A. and Institute Pasteur
Inventors:
Marie-Paule Kieny, Guy Rautmann, Jean-Pierre Lecocq, Simon Wain Hobson, Marc Girard, Luc Montagnier
Abstract: The invention relates to a new probe for detecting a specified nucleic acid sequence. It consists of a recombinant DNA containing an insert complementary to the nucleic acid sequence to be detected and nuclecic acid sequences derived from the DNA (+) of phage M13, the bases which participate in the composition of this recombinant DNA, in particular the thymine groups, being replaced by 5-bromouracil groups. The invention also relates to a method for manufacturing this probe, this method comprising the culturing of cell hosts, more especially E. coli, which are auxotrophic for thymine in a medium containing a limiting concentration of thymine and containing 5-bromouracil. After the requisite incubation time, the supernatant is removed and the probe is recovered from the bacterial cells.
Type:
Grant
Filed:
July 11, 1989
Date of Patent:
December 18, 1990
Assignees:
Institute Pasteur, Centre National de la Recherche Scientifique